In male mice fed a methionine-choline-deficient diet for 6 weeks, which results in hepatic steatosis, oxidative stress, inflammation and fibrosis [144], alirocumab therapy led to reduced numbers of inflammatory cells and lower fibrosis stage, indicating that PCSK9 inhibition may serve as a potential therapeutic approach for NASH (Figure 3). Here, PCSK9 is linked to metabolic dysfunction-associated steatohepatitis.